Stallergenes - Articles and news items

dust mite stg320

Stallergenes announces the approval in Japan of STG320, the first sublingual immunotherapy tablet for the treatment of house dust mite allergy

Industry news / 30 March 2015 / Victoria White

Stallergenes has announced that its partner, Shionogi & Co., Ltd has received the approval of STG320 from the Japanese health authorities…

Stallergenes logo

STALLERGENES and ActoGeniX to develop an innovative new class of oral allergy treatments

Industry news / 21 November 2014 / STALLERGENES / ActoGeniX

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments…

Stallergenes logo

Q3 revenue growth of 3.6% driven by positive performance of sublingual immunotherapy treatments

Industry news / 23 October 2013 / Stallergenes

Sublingual immunotherapy sales continued to grow in the 3rd quarter thanks notably to the fast adoption of Oralair® in France…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...